A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma

PeerJ

Xinxin Ren¹  Shuyi Zhou²  Zhijie Xu³  Geting Wu³  Yuanliang Yan⁴  Long Qian⁴  Xiang Wang⁴  Xi Chen⁴  Jie Wei⁴  Shuangshuang Zeng⁴  Zhicheng Gong⁴  Xue Yang⁴ 

[1] Center for Molecular Medicine, Xiangya Hospital, Key Laboratory of Molecular Radiation Oncology of Hunan Province, Central South University, Changsha, Hunan, China;Department of General Surgery, Hunan Provincial People’s Hospital Xingsha Branch (People’s Hospital of Changsha County), Changsha, Hunan, China;Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China;Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China;

关键词: NTRK2;    Lung adenocarcinoma;    Expression;    Diagnosis;    Prognosis;   

DOI  :  10.7717/peerj.7125

来源: DOAJ

【 摘 要 】

Neurotrophic receptor tyrosine kinase 2 (NTRK2) is a member of the tropomyosin receptor kinase family associated with the tumor development. However, the detailed function of NTRK2 in lung cancer, especially in lung adenocarcinoma (LUAD), is still not fully understood. Here, we investigated the effects of NTRK2 on LUAD biology. Through analyzing bioinformatics data derived from several databases, such as Oncomine, Gene Expression Profiling Interactive Analysis and UALCAN, we found that NTRK2 expression was significantly decreased in LUAD tissues. Clinical data acquired from Wanderer database, which is linked to The Cancer Genome Atlas database, demonstrated that the expression and methylation site of NTRK2 were significantly related to the clinical characteristics and prognosis of LUAD. Furthermore, NTRK2 expression was increased remarkably after treatment with the protein kinase B (AKT) inhibitor MK2206 and the anticancer agent actinomycin D. Functional enrichment analysis of NTRK2-associated coexpression genes was further conducted. Together, our results suggested that downregulated NTRK2 might be used in the diagnostic and prognostic evaluation of LUAD patients, or as a potential therapeutic target for the treatment of LUAD.

【 授权许可】

Unknown